

# Our company

Thermo Fisher Scientific is the world leader in serving science. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or developing and manufacturing life-changing medicines, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services.



## 2024 HIGHLIGHTS<sup>1</sup>



**#18**  
Fortune’s America’s Most Innovative  
Companies 2024



**29%**  
reduction in Scope 1+2 emissions from  
2018 baseline



**\$1.4B**  
R&D investment



**4,800+**  
nonprofits supported<sup>2</sup>

## MISSION

**Our Mission is to enable our customers to make the world healthier, cleaner and safer.**


We fulfill our Mission in countless ways, making a positive impact on the world through our work. Here are just a few examples from 2024.





**Healthier**

Advanced life sciences and precision medicine by supporting the U.K. Biobank Pharma Proteomics Project with our Olink™ technology. The project will analyze over 5,400 proteins from 600,000 samples to find biomarkers for disease prediction, diagnosis, and treatment, revealing a new frontier of health insights.



**Cleaner**

Enabled research on life’s secrets with our Thermo Scientific™ Phenom™ XL G2 Scanning Electron Microscope, which scientists are using for nanometer-scale observation of mineral and microorganism samples from Mount Fagradalsfjall’s newly formed lava tubes. Funded by National Geographic, this research offers insights into subterranean life on Earth and potentially Mars.



**Safer**

Improved organ transplant patient outcomes with more personalized pre-transplant matching and post-transplant monitoring. A new risk assessment helps doctors evaluate a potential patient based on their unique immune profile, and for kidney transplants—the most common globally—our new diagnostic test provides ongoing, non-invasive, post-transplant rejection risk analysis.

**AT A GLANCE<sup>1</sup>**

**\$42B**  
revenue

**120,000**  
colleagues

**\$1.4B R&D**  
investment

**Brands**

Our industry-leading brands enable our customers to push science and technology a step beyond where they are today.

**thermo**  
scientific

**applied**  
biosystems

**invitrogen**

**f** **fisher** scientific

**patheon**

**unity**  
lab services

**ppd**

**Values**

Our 4i Values of Integrity, Intensity, Innovation and Involvement are the foundation of our culture and fundamental to our growth.

**Integrity**

Honor commitments, communicate openly and demonstrate the highest ethical standards

**Intensity**

Be determined to deliver results with speed, excellence and a passion to succeed

**Innovation**

Create value by transforming knowledge and ideas into differentiated products and services for our customers

**Involvement**

Make connections to work as one global team, embracing unique perspectives and treating others with dignity and respect







## Innovation

At Thermo Fisher, our focus on high-impact innovation enables our customers to address some of the world’s greatest challenges. As science continues to advance at a rapid pace, our customers rely on us as a trusted partner to deliver transformative technologies and services that help them break new ground in their important work.

### Getting new medicines and therapies to patients faster

To accelerate and simplify the complex journey of drug discovery and development, Thermo Fisher launched our [Accelerator™ Drug Development](#) solution in 2024. This truly unique offering leverages our unparalleled capabilities to provide a customizable suite of manufacturing, clinical research and clinical supply chain services to emerging biotechs and large pharmaceutical companies.

Accelerator™ Drug Development supports our customers at every stage of the critical drug development process, enabling them to improve their return on R&D investments while improving the lives of patients in need.

*“Thermo Fisher is transforming drug development and manufacturing processes to support customers as they move critical programs forward to tackle global health challenges with speed, quality, and efficiency.”*

**Mike Shafer**, Executive Vice President and President, Biopharma Services, Thermo Fisher Scientific

### A more personalized approach to cancer treatment

To help accelerate research into new treatments for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), Thermo Fisher has partnered with the National Cancer Institute on the myeloMATCH (Molecular Analysis for Therapy Choice) precision medicine umbrella trial. MDS is a group of blood disorders characterized by abnormal production of blood cells in bone marrow, which can progress to AML — one of the most common types of leukemia. An aggressive cancer, it has a five-year survival rate of only 30% to 40% for individuals under age 60. Rapid detection and effective treatment are essential to improve patient outcomes.

The myeloMATCH study will use our [Ion Torrent™ Genexus™ System](#), a next-generation sequencing instrument, to test patients’ bone marrow and blood for specific genetic biomarkers. The system is designed to deliver results in a single day, enabling clinical sites to more quickly match patients with appropriate clinical trials based on their unique cancer profile.

### Expanding access to advanced cancer diagnostics

To increase patient access to affordable, advanced genomic testing for cancer, Thermo Fisher is collaborating with the National University Hospital, Singapore (NUH), and Mirxes, a Singapore-headquartered RNA technology company, to develop next-generation sequencing testing solutions. By advancing cancer research tailored to addressing the needs of the Southeast Asian population, we can support healthcare providers in more rapidly selecting targeted therapy for individual patients.

“NUH’s deep clinical expertise combined with the cutting-edge advancements of biotechnology capabilities and research holds immense promise for the future of cancer care. This collaborative approach will empower us to refine early detection methods and deliver even more precise diagnoses and treatments, propelling us towards optimized clinical outcomes in the fight against cancer,” said Associate Professor Tan Soo Yong, head & senior consultant, Department of Pathology, NUH, when the collaboration was announced in July 2024.

### A once-in-a-decade innovation

To support everything from clean energy to quantum computing, Thermo Fisher launched the groundbreaking [Thermo Scientific™ Iliad™ Scanning Transmission Electron Microscope](#). The Iliad offers a seamless and user-friendly workflow that integrates a number of our advanced analytical technologies, including electron energy loss spectroscopy (EELS), which can—among other things—analyze lithium, a key component in battery development. The Iliad incorporates our most innovative high-resolution spectrometer to accurately determine the composition of materials, as well as our proprietary energy filter for detailed imaging and chemical analysis of samples. This technology provides researchers with deeper insights into the chemical nature of the most sophisticated materials, down to the atomic level.

“It’s one thing to write papers on EELS quantification, it is far more exciting to see these ideas also implemented in a product that will really change the user experience,” said Professor Jo Verbeeck, University of Antwerp, who collaborated on the development of Iliad.



## Our operating discipline

To enable our customers' success in an increasingly competitive global environment, we leverage our Practical Process Improvement (PPI) Business System, a deeply ingrained philosophy of operational excellence that allows us to optimize processes, solve challenges and reduce inefficiencies. Initiated by our colleagues, PPI helps ensure we work smarter for and deliver greater value to our customers. Our teams worldwide are empowered to find a better way every day, driving productivity and improving product and service quality to enhance the customer and colleague experience.



## About this content

Our Corporate Social Responsibility (CSR) website reflects our commitment to society and our stakeholders, and details our progress on relevant priorities. It is regularly updated to feature the latest on our CSR programs, achievements and performance.

In 2024, we completed the acquisition of Olink Holding AB (publ) ("Olink"), a provider of leading solutions for advanced proteomics discovery and development. This content and data is inclusive of all Thermo Fisher Scientific entities, including Olink Proteomics AB (559046-8632) and Phadia AB (556041-3204).

All 2024 data covers the period from January 1 to December 31, 2024 and can be found aggregated in our [Data summary](#). For select environmental performance indicators, our company's third-party auditor has provided independent external assurance. Assured data is clearly marked in the [Data summary](#), and a copy of the assurance statement is available in our [Reporting hub](#) providing details on the assurance scope, standards used, work undertaken and conclusions.

For questions or comments regarding this content or our CSR strategy, please contact us at [sustainability@thermofisher.com](mailto:sustainability@thermofisher.com).

© 2025 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. ACT. The ACT Ecolabel is a trademark of My Green Lab. AdvaMed is a trademark of Advanced Medical Technology Association. DuPont is a trademark of DuPont Specialty Products USA, LLC. ENERGY STAR is a registered trademark of the U.S. Environmental Protection Agency. Innovation Nation is a trademark of The Edison Institute. Junior Innovators Challenge is a trademark of the Society for Science & the Public. Project HOPE is a trademark of Project HOPE-The People-to-People Health Foundation, Inc. Responsible Minerals Initiative is a trademark of Responsible Business Alliance, Inc. RightCycle is a trademark of Kimberly-Clark Worldwide, Inc. Society for Science is a trademark of Society for Science & the Public. Science Based Targets initiative is a trademark of Science Based Targets Initiative. Tyvek is a trademark of DuPont Safety & Construction, Inc. World Economic Forum is a trademark of World Economic Forum